
Whitepapers
Spark Therapeutics Announces $850 000 price tag of gene therapy treatment Luxturna
Spark Therapeutics has announced its recently approved Luxturna (voretigene neparvovec-rzyl), a gene therapy treatment for biallelic RPE65 mutation-associated retinal dystrophy will cost $425 000 per